Published in Hepatology on February 01, 2013
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Heterogeneous claudin-1 expression in human liver. Hepatology (2013) 1.11
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Noninvasive assessment of liver fibrosis. Hepatology (2010) 3.86
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63
Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol (2005) 2.39
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
Viral hepatitis in liver transplantation. Gastroenterology (2012) 1.59
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol (2010) 1.59
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol (2011) 1.50
[Use of complementary and alternative medicine in patients with chronic hepatitis C]. Med Clin (Barc) (2004) 1.44
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.28
Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol (2012) 1.26
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol (2009) 1.17
ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol (2012) 1.15
Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) (2011) 1.14
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology (2010) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology (2006) 1.05
Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol (2009) 1.04
Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl (2004) 1.03
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther (2006) 1.01
Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation (2004) 1.00
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology (2013) 0.99
Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique. Antimicrob Agents Chemother (2009) 0.99
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol (2005) 0.98
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) (2003) 0.97
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One (2012) 0.92
Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat? J Hepatol (2006) 0.92
Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother (2008) 0.91
Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol (2010) 0.91
Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. J Gen Virol (2010) 0.90
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis (2007) 0.90
Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology (2009) 0.89
Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum (2006) 0.89
Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl (2008) 0.88
Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol (2012) 0.87
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther (2009) 0.86
Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS One (2012) 0.86
[Hepatitis C in Spain]. Med Clin (Barc) (2006) 0.85
DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine (2002) 0.84
Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation. Transplantation (2005) 0.84
Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2014) 0.83
Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol (2004) 0.82
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther (2014) 0.82
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut (2013) 0.81
Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. Medicine (Baltimore) (2013) 0.81
Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. PLoS One (2011) 0.81
Viral hepatitis and liver transplantation: pathogenesis, prevention and therapy of recurrent disease. Dig Dis (2014) 0.79
Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case-control study. Clin Transplant (2014) 0.78
Treating hepatitis C in patients with cirrhosis: the effort is worth it. J Hepatol (2010) 0.78
Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants. Microb Drug Resist (2011) 0.78
Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. J Gen Virol (2015) 0.78
Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. J Rheumatol (2006) 0.78
Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant (2013) 0.78
A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. PLoS One (2012) 0.78
Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". J Hepatol (2015) 0.77
MR elastography to assess liver fibrosis. Radiology (2008) 0.77
Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. J Virol (2013) 0.77
[Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation]. Gastroenterol Hepatol (2012) 0.77
Interferon free regimens for the "difficult-to-treat": are we there? J Hepatol (2013) 0.77
Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. J Hepatol (2012) 0.77
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. Gastroenterol Hepatol (2012) 0.76
[The molecular biology of hepatitis C virus]. Gastroenterol Hepatol (2013) 0.76
Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. Dig Dis (2016) 0.76
Imaging of hepatitis C virus infection in liver grafts after liver transplantation. J Hepatol (2013) 0.75
How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation? Liver Transpl (2008) 0.75
Hepatitis C virus and human immunodeficiency virus: the un-won battle. Hepatology (2007) 0.75
Treatment of HCV infection in patients with advanced cirrhosis. Hepatology (2004) 0.75
Living donor liver transplantation and hepatitis C: lessons from the learning curve? Liver Transpl (2007) 0.75
The extrahepatic contribution to HCV plasma viremia. J Hepatol (2006) 0.75
HCV: alive and kicking in living donor liver grafts? Hepatology (2005) 0.75
Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS One (2017) 0.75
Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. Eur J Gastroenterol Hepatol (2011) 0.75
[Current epidemiology of viral hepatitis: who is affected and who can be protected?]. Enferm Infecc Microbiol Clin (2004) 0.75
Goodbye from Barcelona! J Hepatol (2004) 0.75
[Telaprevir in HCV-monoinfected patients with failure to prior treatment]. Enferm Infecc Microbiol Clin (2013) 0.75
Advances in hepatitis C therapies. Expert Opin Pharmacother (2015) 0.75
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. Enferm Infecc Microbiol Clin (2005) 0.75
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. Liver Transpl (2013) 0.75
[Hepatic elastography. Position paper of the Catalan Society of Gastroenterology]. Gastroenterol Hepatol (2011) 0.75
Hepatitis C treatment for patients post liver transplant. Curr Opin Organ Transplant (2015) 0.75
[Usefulness of liver stiffness measurement after antiviral response in chronic hepatitis C]. Enferm Infecc Microbiol Clin (2013) 0.75